Beijing Centergate Technologies announced that the application for marketing authorization of the hydrochloride bromhexine injection (specification: 2ml:4mg) from its subsidiary, Duoduo Pharmaceutical, has been accepted by the National Medical Products Administration. This Pharmaceutical is used to treat chronic bronchitis and other respiratory diseases in cases where oral administration is difficult.